VRDN

Viridian Therapeutics, Inc. (VRDN) - 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated October 17, 2025, details two material definitive agreements entered into by Viridian Therapeutics, Inc. to secure funding for its clinical development and commercialization efforts. The filing does not contain a standard financial reporting period (e.g., quarterly or annual results) but focuses on specific corporate events occurring on the report date.

Key Financial Metrics and Capital Structure

The filing outlines significant capital inflows and debt obligations:

• Revenue Participation Sale: The Company sold rights to certain U.S. revenue streams to DRI Healthcare Acquisitions LP for up to $300 million in total consideration.
• Immediate Cash Inflow: $55 million was paid on the signing date of the revenue participation agreement.
• Debt Facility: The Company secured a new term loan facility of up to $300 million via an amendment to its Loan and Security Agreement with Hercules Capital, Inc.
• Initial Debt Draw: $50 million was drawn immediately upon execution of the loan amendment.
• Interest Rate: The new term loan bears interest at the greater of 8.95% or 1.45% above the Prime Rate, capped at 9.45%.
• Liquidity: The agreements provide immediate liquidity of approximately $105 million ($55M equity-like + $50M debt) with potential for additional tranches based on milestones.

Material Changes and Agreement Terms

Revenue Participation Agreement (DRI):

• Milestone Payments: Remaining consideration is contingent on clinical and regulatory milestones:
  • $25 million for VRDN-003 Phase 3 trial milestones.
  • $75 million for FDA approval of veligrotug.
  • $15 million if both the above are met.
  • $50 million for FDA approval of VRDN-003.
  • $50 million (at Company election) for achieving $1.1 billion in net sales.
  • $30 million potential additional payment based on future financial terms.
• Royalties: The Company must pay tiered royalties on U.S. net sales:
  • 7.5% on sales up to $600 million (potentially increasing to low-double digits if VRDN-003 approval is delayed).
  • 0.8% on sales between $600 million and $900 million.
  • 0.25% on sales between $900 million and $2 billion.
  • No royalty on sales exceeding $2 billion.
• Debt Limitation: The agreement limits the incurrence of certain indebtedness, a restriction that terminates after veligrotug receives U.S. marketing approval.

Loan Amendment (Hercules):

• Tranche Structure: The $300 million facility is divided into five tranches. Tranche 1 ($100M) is partially drawn ($50M) with $25M available through Sept 2026 and another $25M through Dec 2026. Tranches 2, 3, and 4 ($50M each) are subject to regulatory or revenue milestones. Tranche 5 ($50M) requires lender committee approval.
• Repayment Terms: Interest-only payments are required through October 17, 2029 (extendable to 2030 if milestones are met). Principal repayment begins thereafter in equal monthly installments.
• Fees: An end-of-term fee of 4.25% applies if repaid by Oct 2027; 6% applies if repaid after that date.
• Collateral: Obligations are secured by substantially all assets of the Borrower.

Outlook, Risks, and Contingencies

Management Commentary and Outlook: The Company is leveraging its pipeline (veligrotug and VRDN-003) to secure non-dilutive capital. The structure of the DRI deal suggests confidence in achieving regulatory approvals and significant commercial sales, while the Hercules loan provides a bridge to commercialization.

Risks and Contingencies:

• Milestone Dependency: A significant portion of the $300 million potential revenue participation payment and the $200 million in remaining loan tranches is contingent on achieving specific clinical, regulatory, and sales milestones.
• Cost of Capital: The loan carries a high interest rate (minimum 8.95%) and substantial end-of-term fees (up to 6%).
• Future Cash Flow Obligations: The Company assumes long-term royalty obligations on future U.S. net sales, which could impact future profitability.
• Change of Control: The revenue participation agreement includes provisions requiring repayment of a multiplier of consideration paid in the event of a change of control.

Key Facts for Investor Verification

• Verify the specific dates and definitions of the "specified dates" for milestone payments in the DRI agreement.
• Confirm the current status of the REVEAL-1 and REVEAL-2 Phase 3 trials to assess the likelihood of the $25 million milestone payment.
• Review the "multiplier" terms for repayment in the event of a change of control or early termination of the DRI agreement.
• Monitor the achievement of regulatory milestones required to access Tranches 2, 3, and 4 of the Hercules loan.
• Assess the impact of the 7.5% royalty rate on projected net margins for veligrotug and VRDN-003.